Disease relevance of Deracoxib

• Exposure of osteosarcoma cells to cytotoxic concentrations of deracoxib and piroxicam did not result in DNA fragmentation [1].
• Neither deracoxib nor piroxicam induced sufficient toxicity in fibroblasts to reach an IC50 [1].
• In vivo effects of carprofen, deracoxib, and etodolac on prostanoid production in blood, gastric mucosa, and synovial fluid in dogs with chronic osteoarthritis [2].
• The effects of epidural deracoxib on the ground reaction forces in an acute stifle synovitis model [3].
• CONCLUSIONS: Epidural administration of deracoxib is effective at providing analgesia in an acute joint pain model; however, it does not appear to be more effective than systemic administration [3].

High impact information on Deracoxib

• Effects of deracoxib or buffered aspirin on the gastric mucosa of healthy dogs [4].
• Treatment with high dosages of aspirin, but not deracoxib, should be discontinued prior to evaluation of thyroid function [5].
• Amputation or radiation therapy was declined; the dog was treated conservatively with doxycycline and deracoxib [6].
• OBJECTIVE: To identify factors associated with gastrointestinal tract perforation in dogs being treated with a selective cyclooxygenase-2 (COX-2) inhibitor (deracoxib) [7].
• PROCEDURE: The Novartis Animal Health pharmacovigilance database was searched for records of dogs treated with deracoxib in which gastrointestinal tract perforation was documented [7].

Chemical compound and disease context of Deracoxib

• CONCLUSIONS AND CLINICAL RELEVANCE: Intermediate and high concentrations of deracoxib and high concentrations of piroxicam were cytotoxic to osteosarcoma cells; neither drug inhibited cell viability at typical plasma concentrations in dogs [1].
• Oral dosing of placebo, carprofen, or deracoxib was done 30 minutes before intraarticular injection of urate crystal suspension for induction of synovitis [8].
• OBJECTIVE: To evaluate the efficacy of epidurally administered deracoxib to mediate the signs of a sodium urate crystal-induced stifle synovitis in dogs, and to compare the efficacy of epidural versus subcutaneously administered deracoxib [3].

Biological context of Deracoxib

• Transepithelial electrical resistance (TER) and mucosal-to-serosal fluxes of 3H-mannitol were monitored as indices of barrier function in the presence of flunixin or deracoxib [9].
• OBJECTIVE: To determine whether exposure of canine osteosarcoma cells to deracoxib or piroxicam results in decreased viability, whether the cytotoxic effects of deracoxib and piroxicam involve induction of apoptosis, and whether deracoxib is a more potent inhibitor of osteosarcoma cell growth than piroxicam [1].
• The pharmacokinetics of deracoxib in seven healthy cats were determined following a single oral (1 mg/kg) dose [10].

Anatomical context of Deracoxib

• Deracoxib inhibited viability of cells at concentrations that did not affect fibroblast viability [1].
• Effects of cyclooxygenase inhibitors flunixin and deracoxib on permeability of ischaemic-injured equine jejunum [9].
• Addition of misoprostol or replacement of flunixin with deracoxib may ameliorate effects of COX inhibitors on recovering mucosa [9].
• RESULTS: Concentration of deracoxib required for 50% inhibition of cell viability (IC50) was reached in all 3 osteosarcoma cell lines and ranged from 70 to 150 microM, whereas the IC50 for piroxicam was only reached in the POS cell line at 500 microM [1].

Associations of Deracoxib with other chemical compounds

• Twenty-four healthy, mixed-breed hound-type dogs were evenly and randomly assigned to a placebo control group, one of four dosages of deracoxib (0.3, 1, 3, or 10 mg/kg), or carprofen (2.2 mg/kg) [8].

Gene context of Deracoxib

• OBJECTIVE: To compare the effects of deracoxib, a highly selective canine COX-2 inhibitor, with flunixin on in vitro recovery of ischaemic-injured equine jejunum [9].

Analytical, diagnostic and therapeutic context of Deracoxib

• The development of the assay allowed the determination of pharmacokinetic parameters after oral administration of deracoxib in cats and would be suitable for other pharmacokinetic studies [11].
• CLINICAL RELEVANCE: Injectable deracoxib is effective in providing analgesia in acute inflammatory conditions of synovial joints [3].
• A new HPLC procedure for the determination of deracoxib, a selective cyclooxygenase-2 inhibitor, has been developed and validated [11].
• Determination of deracoxib in feline plasma samples using high performance liquid chromatography [11].

References